Lilly celebrates 100 years of insulin at EXPO 2020

 Dubai, 15th of March 2022 –  Eli Lilly (Suisse) S.A., Branch, hosted a panel discussion at the US pavilion in EXPO 2020 in the occasion of 100 years of insulin. The panel included Dr. Abdulrazaq Al Madani – President of Gulf Group for the study of Diabetes, and Dr. Robert Heine – Vice President Lilly Diabetes Medical and Distinguished Lilly Scholar, where the discussion focused on the journey of innovation throughout 50 years of UAE and 100 years of insulin.

Opening the discussion, Dr. Madani reflected on the outstanding economic and healthcare developments in the UAE throughout the past 50 years, focusing on the importance of the progress made in awareness and education through the collaboration between government bodies, the Emirates Diabetes Society, healthcare professionals, and the pharmaceutical industry. Dr. Madani then took the audience through the journey of diabetes treatment, citing improvement of quality of care and lifestyle for people with diabetes through new medicines development, innovation in devices, and guidelines for disease management. Finally, Dr. Madani emphasized the role of data and real-world evidence in making informed -decisions and shaping future plans tackling education, prevention, management, and avoiding complication.

During the meeting, Lilly announced initiating preparations for a real-world evidence (RWE) study focusing on the burden of diabetes in the UAE, where we will look at short term and long-term diabetes complications data from 500 patients across 5 key hospitals across the UAE. This benchmark RWE study aims to address the gaps in the burden of diabetes data in the region.

From his side, Dr. Robert Heine started by addressing the global burden of diabetes and recent trends. Currently, diabetes affects more than 420 million people around the world and that number could increase to more than 600 million over the next 20 years. Dr. Heine acknowledged the acceleration of drugs development since the initial discovery of insulin in 1920, and the first human-dose administration almost 100 years ago. He also highlighted the need for informed decision-making through data generated from RWE to support regulators, payers, and physicians translating clinical trials to real-life practice.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. The company was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

For adverse events and safety reporting, please send an email to PV-MEA@lilly.com

For further information about Lilly and Lilly products please contact us at the below address:

UAE: Bldg. 25 – 6th Floor, Dubai Health Care City, Dubai, UAE, P.O. Box # 25319, Tel: (+971 4) 453 7800, Fax: (+971 4) 436 2399

Ends